The role of the transcription factor Blimp-1 in T cells in anti-PD1 immunotherapy in non-small cell lung cancer 2258857
Immune checkpoint inhibitors targeting the interaction between PD1 and PDL1 are effective for immunotherapy in non-small cell lung cancer (NSCLC), which is the leading cause of cancer related death in the world. However, only subgroups of patients respond to therapy suggesting the existence of resistance mechanis...